As healthcare marketers strive to keep pace with data technologies for better targeting and conversion, budgeting for 2019 becomes a formidable challenge. Questions about competitive advantages and cost-effectiveness drive conversations. Yet, the focus of forward-thinkers is shifting to better data for targeting faster and sooner in the engagement lifecycle. “We are seeing a … [Read more...]
Schedule Your Personalized Marketing Technology Workshop
PharmaLeaders is pleased to provide our subscribers with a special offer from our webinar partner and presenter, Collaborative Marketing Solutions (CMS). Get your own Marketing Tech Workshop for Life Sciences: Full Day or Half Day Sessions Facilitated Exercises & Group Breakout Sessions Customer Segmentation Project Prioritization Project Implementation … [Read more...]
Register for Webinar – 10 Hot Technologies Impacting Life Sciences Marketing
Brought to by PharmaLeaders & Presented by Collaborative Marketing Solutions Webinar: 10 Hot Technologies Impacting Life Sciences Marketing July 24 @ 1 pm Eastern [REGISTER NOW] Registration closed; this event has passed. Are you curious about ways that other organizations in the life sciences use the latest technologies to deliver dynamic and engaging programs? … [Read more...]
Survey Finds Parkinson’s Disease Impact on Quality of Life Is Significant
An accurate diagnosis for Parkinson’s disease is often complicated and delayed by an array of symptoms resembling other conditions, according to a new survey from Health Union. The survey involved more than 1,100 individuals currently living with Parkinson’s disease and was released through Health Union’s newest online community, ParkinsonsDisease.net. It finds patients are … [Read more...]
Teewinot Life Sciences and Noramco sign letter of intent to produce cannabinoids with CannSynthesis™ biocatalysis technology
Teewinot Life Sciences (Teewinot), the market leader in biocatalytic technologies for the production of pharmaceutical-grade cannabinoids, and Noramco, a global leading producer of controlled-substance active pharmaceutical ingredients (APIs), today signed a letter of intent to enter the commercial cannabinoids market using proprietary CannSynthesis™ technology. The agreement … [Read more...]